Table 2.

Incidence of primary endpoints in rheumatoid arthritis patients assigned to PPSV23 or placebo

	Vaccine group (n = 464)		Placebo group (n = 436)
	Incidence rate per 1000 patient-years (n)	95% CI	Incidence rate per 1000 patient-years (n)	95% CI	P value
Pneumococcal pneumonia	2.6 (2)	0.7–9.5	1.4 (1)	0.3–8.0	0.523
Nonpneumococcal pneumonia	19.6 (15)	11.9–32.3	19.9 (14)	11.9–33.4	0.985
All-cause pneumonia	22.2 (17)	13.9–35.6	21.3 (15)	12.9–35.2	0.856

PPSV23 23-valent pneumococcal polysaccharide vaccine, CI confidence interval